Recently, Bio-Thera Solutions, Ltd. (Bio-Thera)’s BAT6021 injection and BAT6005 injection of innovative drugs have been approved for clinical use, which means the new progress has been made in the field of tumor treatment.
In recent years, Medicilon has continued to expand and innovate in the cutting-edge field of biotechnology drug research and development, and has built a functional and well-equipped protein/antibody pharmacokinetic research platform and a biotechnology drug non-human primate safety evaluation technical service platform, which is flexible using various methods such as ELISA, ECL, TRFIA, CLIA, IF, IP, CoIP, qPCR, FACS, ELISpot, enzymology, etc., to support the preclinical research evaluation of various protein and antibody drugs.
Medicilon provides antibody drugs discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services. As of the end of June 2023, Medicilon has successfully assisted in the clinical approval of 31 antibody drugs (8 approved by FDA and NMPA, 1 approved by NMPA and TGA, 1 approved by FDA, NMPA, and TGA) and has multiple antibody projects under development.
BAT6021 is a differentiated anti-TIGIT monoclonal antibody developed by Bio-Thera, which is intended to be developed for tumor treatment. TIGIT is an immunoglobulin superfamily protein that is highly expressed on the surface of activated NK cells, CD4+ T cells, CD8+ T cells and immunosuppressive Tregs. PVR, the main ligand of TIGIT, is highly expressed on the surface of a variety of solid tumor cells and dendritic cells. BAT6021 can block the combination of TIGIT and CD155 (PVR), thereby restoring the functions of T cells and NK cells. The differentiated BAT6021 has ADCC enhancement function, which can eliminate immunosuppressive Tregs cells through the enhanced ADCC function, and strengthen the combination of T cells and DC cells, thereby improving the response of antigen-specific T cells and improving the effect of tumor immunotherapy.
BAT6005 is an anti-TIGIT monoclonal antibody developed by Bio-Thera, which is intended to be developed for tumor treatment. TIGIT is an immunoglobulin superfamily protein that is highly expressed on the surface of activated NK cells, CD4+ T cells, CD8+ T cells and immunosuppressive Tregs. PVR, the main ligand of TIGIT, is highly expressed on the surface of a variety of solid tumor cells and dendritic cells. BAT6005 can block the combination of TIGIT and CD155 (PVR), thereby restoring the functions of T cells and NK cells. In addition, BAT6005 has a normal ADCC effect function, which can eliminate immunosuppressive Tregs cells through ADCC function.
Just as Bio-Thera adheres to the concept of “Innovation is only for life” and is committed to the research and development of a new generation of antibody drugs; Medicilon also regards “Innovation-driven, quality first” as its development philosophy, and is committed to provide a full range of pre-clinical new drug research services to global pharmaceutical companies, research institutions and scientific research. Similar ideas and visions have prompted the two parties to reach collaboration again and again and have successful results one by one. The collaboration between Medicilon and Bio-Thera is that like-minded people go to the future of human health, and it also shows Bio-Thera’s high recognition of Medicilon.
Medicilon has also repaid Bio-Thera’s trust with professional technology and rigorous attitude. From the beginning of the project, Medicilon has made every effort to promote the project with its rich project experience and high-quality and efficient R&D services. Through the collaboration, Medicilon has accumulated a lot of valuable R&D experiences.
The collaboration between Medicilon and Bio-Thera is continuing and we look forward to the joint efforts and mutual trust of both parties. The collaboration will bear more new drugs and promote the launch of more new biological drugs, which will benefit patients around the world!
The collaboration between Medicilon and Bio-Thera is continuing and we look forward to the joint efforts and mutual trust of both parties. The collaboration will bear more new drugs and promote the launch of more new biological drugs, which will benefit patients around the world!
Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next-generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials, one of which, QLETLI®, a biosimilar to Humira® (adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease or uveitis in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 900 clients globally. Medicilon is proud to contribute to human health in the globe.
Relevant
news
marketing@medicilon.com
